AORT / Artivion, Inc. (AORT) CEO James Mackin on Q2 2022 Results - Earnings Call Transcript

Artivion has used M&A to reposition itself towards growth opportunities in aortic disease care and heart valves. The company's legacy operations contr more_horizontal

ATLANTA , Sept. 14, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today more_horizontal

Here is how Artivion (AORT) and Augmedix, Inc. (AUGX) have performed compared to their sector so far this year. more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Artivion (AORT). While the effectiveness of this hig more_horizontal

Artivion, Inc. (NYSE:AORT ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 AM ET Company Participants Laine Morgan – Gilmartin Group Pat Macki more_horizontal

Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of more_horizontal

Artivion, Inc. has begun to recover from the fallout after its PROACT trial failure. On-X sales almost doubled the 5-year average range in Q1, and man more_horizontal

Artivion, Inc. (NYSE:AORT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Brian Johnston - Vice President, Gilmartin Gr more_horizontal